Core Viewpoint - The announcement from Junshi Bioscience indicates that shareholder Tan Ying Investment plans to reduce its stake by up to 20.53 million shares, representing 2% of the total share capital, through block trading between January 13, 2026, and April 10, 2026, due to fund duration and liquidity arrangements [1]. Group 1: Shareholder Actions - Tan Ying Investment currently holds 59.45 million shares, accounting for 5.79% of the total share capital [1]. - The initial holding of Tan Ying Investment was 71.45 million shares, which represented 6.96% of the total share capital [2]. - Since June 20, 2025, Tan Ying Investment has cumulatively reduced its holdings by 12 million shares, realizing approximately 526 million yuan [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Bioscience reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [3]. - As of September 30, 2025, the number of shareholders for Junshi Bioscience was 35,900, an increase of 15.17% from the previous period [3]. Group 3: Market Performance - As of the latest report, Junshi Bioscience's stock price has decreased by 1.42%, with a trading volume of 173 million yuan and a turnover rate of 0.63%, bringing the total market capitalization to 36.478 billion yuan [3]. - The stock has experienced a 30% increase year-to-date, but has seen declines of 2.15% over the last five trading days, 3.50% over the last 20 days, and 22.15% over the last 60 days [3].

Group 1 - Haitai Flavor Industry plans to distribute cash dividends of no less than 80% of the net profit attributable to shareholders for the next three years (2025-2027) [2] - Haitai will implement a special dividend plan for 2025, distributing 3.0 yuan (including tax) for every 10 shares [2] Group 2 - Xusheng Group's controlling shareholder is planning a change in control, leading to a suspension of trading for the company's stock starting December 19, 2025 [3] Group 3 - Guandong Quantum's chairman, Lü Pin, has passed away, and the company expresses deep condolences [4] Group 4 - Former controlling shareholder of Guao Technology, Chen Chongjun, has been sentenced to six years in prison for manipulating the securities market, with a fine of 4 million yuan [5] - The company states that this judgment will not significantly impact its operations [5] Group 5 - Tianfeng Securities plans to extend a 4 billion yuan subordinated debt for one year and reduce the interest rate from 5% to 4% [6] Group 6 - Zhongwei Company is planning to acquire controlling stakes in Hangzhou Zhonggui Electronic Technology Co., Ltd., leading to a stock suspension starting December 19, 2025 [7] Group 7 - Shandong Highway intends to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities, which will reduce the company's consolidated profit for 2025 by the same amount [8] Group 8 - HeFu China has experienced a significant stock price increase of 349.25% from October 28 to December 18, 2025, despite being in a loss position [9] - The company warns of risks related to high valuation and operational performance [9] Group 9 - Xizang Pharmaceutical plans to repurchase shares worth between 170 million and 200 million yuan, with a maximum repurchase price of 55 yuan per share [11] Group 10 - Junshi Biological's major shareholder, Shanghai Tanying, plans to reduce its stake by up to 2% through block trading [12] Group 11 - Dazhong Mining's major shareholders and executives plan to reduce their holdings by up to 1.44% due to personal financial needs [13] Group 12 - Ruicheng Environmental Protection's shareholder plans to reduce its stake by up to 3% [14] Group 13 - Allianz Vision's actual controller Xu Jin plans to reduce his stake by up to 0.9609% [15] Group 14 - Yidong Electronics' controlling shareholder's concerted action reduced their holdings by 1% from December 10 to December 17 [16] Group 15 - Ningbo Construction won a project bid worth 747 million yuan for infrastructure enhancement [18] Group 16 - Qinglong Pipe Industry signed a sales contract worth 55.27 million yuan for a water diversion project [19] Group 17 - Zhongfutong received a selection notice for a procurement project with estimated amounts of 411 million yuan and 162 million yuan [20] Group 18 - Shikong Technology won a bid for a smart cultural tourism integration project worth 141 million yuan [21]

Group 1: Shareholding Increase - Dazhong Mining's director and general manager Lin Pusheng plans to increase his shareholding by no less than 15.08 million shares [2] - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [2] - Tibet Pharmaceutical intends to repurchase shares worth between 170 million to 200 million yuan for equity incentives or employee stock ownership plans [2] Group 2: Shareholding Decrease - Lidasin's fifth largest shareholder reduced their stake by 1.56% from December 10 to December 17 [2] - WuXi AppTec's 18 shareholders collectively reduced their holdings by 29.5 million shares from November 26 to December 17 [2] - Feilong Co.'s controlling shareholder recently reduced their stake by 0.59% of the total share capital [2] - Ruicheng Huabao's shareholder plans to reduce their stake by no more than 3% [2] - Xuhul Co.'s shareholder Wang Xiaojun and their concerted parties plan to reduce their holdings by no more than 2.98% [2] - Yidong Electronics' third and fifth largest shareholders recently reduced their holdings by 2.3463 million shares [2] - Junshi Biosciences' Shanghai Tanying plans to reduce its stake by no more than 2% [2] - Huahai Chengke's shareholder intends to reduce their stake by no more than 1% [2] - Boshuo Technology's director Yang Chuanqi and executive Zhou Dan plan to reduce their holdings by no more than 0.011% [2] - Allianz Ruishi's shareholder Xu Jiang plans to reduce their stake by no more than 0.96% [2] - Dazhong Mining's shareholders, including those holding over 5%, the chairman, and senior management, plan to reduce their holdings [2]

Core Viewpoint - On December 18, several A-share listed companies disclosed their shareholding changes, with notable increases in holdings from some companies and reductions from others [1]. Group 1: Shareholding Increases - Dazhong Mining's director and general manager Lin Pushi plans to increase his shareholding by no less than 15.08 million shares [2]. - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [2]. - Tibet Pharmaceutical intends to repurchase shares worth between 170 million to 200 million yuan for equity incentives or employee stock ownership plans [2]. Group 2: Shareholding Reductions - Lidasin's fifth-largest shareholder reduced their stake by 1.56% between December 10 and December 17 [2]. - WuXi AppTec's 18 shareholders collectively reduced their holdings by 29.5 million shares from November 26 to December 17 [2]. - Feilong Co.'s controlling shareholder recently reduced their total shareholding by 0.59% [2]. - Ruichen Environmental's shareholder plans to reduce their stake by no more than 3% [2]. - Lihuk Co.'s shareholder Wang Xiaojun and his concerted actors plan to reduce their holdings by up to 2.98% [2]. - Yidong Electronics' third and fifth largest shareholders recently reduced their holdings by 2.3463 million shares [2]. - Junshi Biosciences' Shanghai Tanying plans to reduce its stake by no more than 2% [2]. - Huahai Chengke's shareholder intends to reduce their stake by no more than 1% [2]. - Boshuo Technology's director Yang Chuanqi and executive Zhou Dan plan to reduce their holdings by no more than 0.011% [2]. - Allianz Vision's chairman Xu Jin plans to reduce his stake by no more than 0.96% [2]. - Dazhong Mining's major shareholders, including the chairman and senior management, plan to reduce their holdings [2].

公告显示，上海檀英持有君实生物股份5945.93万股，股份性质为A股，占公司总股本的5.7914%。 北京商报讯（记者 丁宁）12月18日晚间，君实生物（688180）发布公告称，公司股东上海檀英投资合 伙企业（有限合伙）（以下简称"上海檀英"）长期看好公司的发展，因基金期限与流动性资金安排原 因，计划通过大宗交易的方式减持其持有的公司股份数量不超过2053.38万股，减持比例不超过公司总 股本的2%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年12月18日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告编号：临 2025-075 上海君实生物医药科技股份有限公司 关于持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 ...

Group 1 - Zhongwei Company plans to acquire controlling stake in Hangzhou Zhonggui through share issuance, with stock suspension starting December 19, 2025, for up to 10 trading days [1] - Qibin Group's subsidiary plans to establish Shenzhen Qibin New Energy Technology Co., with a registered capital of 600 million yuan to enhance photovoltaic glass supply chain efficiency [2] - Boying Special Welding's HRSG equipment is primarily matched with heavy gas turbines, with a production cycle of about 6 months, responding to increased demand in the U.S. market [3] Group 2 - Hongda Electronics' associate Jiangsu Zhanxin's application for IPO on the ChiNext has been accepted, with Hongda holding 13.79% of shares prior to the offering [5] - Yinxing Energy plans to acquire 50% stake in Tianjing Shenzhou for 20.15275 million yuan, which will enhance its renewable energy capacity [6] - Nandu Power's controlling shareholder has terminated plans for a change in control, leading to stock resumption on December 19, 2025 [7] Group 3 - Xibu Mining's subsidiary has obtained a mining license for iron resources, supporting sustainable development in the iron resource sector [9] - Shandong Expressway plans to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities [10] - Tianfeng Securities has signed a supplementary agreement to extend the term of a 4 billion yuan subordinated debt by one year, with an adjusted interest rate of 4% [11] Group 4 - Shandong Zhanggu has received an administrative regulatory decision from the Shandong Securities Regulatory Commission for various compliance issues [12] - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company, focusing on acquiring a stake in Ningbo Jiangfeng [13] - Hailianxun has received approval from the CSRC for a share swap merger with Hangzhou Steam Turbine, proceeding with related transactions [14] Group 5 - Luyuan Pharmaceutical reports normal operations with no significant changes in the internal and external business environment [15] - Nanhua Futures has set the H-share public offering price at 12 HKD per share, with expected listing on December 22, 2025 [17] - Visionox plans to invest 3.918 billion yuan in the second phase of the Hefei Guoxian AMOLED production line project, increasing its stake to 37.73% [18] Group 6 - Sichuan Road and Bridge has been acquired by Zhong Postal Insurance, reaching a 5% stake [19] - Boshuo Technology's directors plan to reduce their holdings by up to 18,300 shares [20] - O-film's controlling shareholder transferred 67.7048 million shares to settle debts, maintaining control with a 5.78% stake post-transfer [21] Group 7 - Junshi Biosciences' shareholder plans to reduce holdings by up to 2% through block trading [22] - Lihu Co. plans to reduce holdings by up to 2.98% through various trading methods [23] - Ruichen Environmental plans to reduce holdings by up to 3% through trading [25] Group 8 - Zhongfutong received a winning bid notification for a project worth approximately 411 million yuan [29] - Shikong Technology won a 141 million yuan project for smart cultural tourism integration [30] - Ningbo Construction's subsidiary won a 747 million yuan engineering project [31]

智通财经APP讯，君实生物(688180.SH)发布公告，上海檀英长期看好公司的发展，因基金期限与流动 性资金安排原因，计划通过大宗交易的方式减持其持有的公司股份数量不超过2053.38万股，减持比例 不超过公司总股本的2%。 ...

大股东持股的基本情况 截至本公告披露日，上海檀英投资合伙企业（有限合伙）（以下简称"上海 檀英"）持有上海君实生物医药科技股份有限公司（以下简称"公司"或"君实 生物"）股份 59,459,326 股，股份性质为 A 股，占公司总股本的 5.7914%。上述 股份为公司首次公开发行股票并在上海证券交易所科创板上市（以下简称"IPO"） 前取得的股份，且已于 2021 年 7 月 15 日起解除限售并上市流通。 证券代码：688180 证券简称：君实生物 公告编号：临 2025-075 上海君实生物医药科技股份有限公司 关于持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 2 股东名称 上海檀英 股东身份 控股股东、实控人及一致行动人 □是 √否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他：不适用 持股数量 59,459,326股 持股比例 5.7914% 当前持股股份来源 IPO 前取得：59,459,326股 上述减持主体 ...

格隆汇12月18日丨君实生物(688180.SH)公布，公司于近日收到上海檀英出具的《关于君实生物减持计 划告知函》，上海檀英长期看好公司的发展，因基金期限与流动性资金安排原因，计划通过大宗交易的 方式减持其持有的公司股份数量不超过2053.38万股，减持比例不超过公司总股本的2%。上海檀英为在 中国证券投资基金业协会备案的私募基金，已成功申请适用《上市公司创业投资基金股东减持股份的特 别规定》和《上海证券交易所上市公司创业投资基金股东减持股份实施细则》的减持政策：拟通过大宗 交易方式减持的，在任意连续60日内减持股份的总数不超过公司总股本的2%，自本公告披露之日起15 个交易日后的三个月内进行。 ...